2-butyl-9-methyl-8-(triazol-2-yl)purin-6-amine
Modify Date: 2024-01-11 14:15:19
2-butyl-9-methyl-8-(triazol-2-yl)purin-6-amine structure
|
Common Name | 2-butyl-9-methyl-8-(triazol-2-yl)purin-6-amine | ||
|---|---|---|---|---|
| CAS Number | 496955-42-1 | Molecular Weight | 272.30900 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C12H16N8 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of 2-butyl-9-methyl-8-(triazol-2-yl)purin-6-amineST 1535 is a potent and orally active A2A adenosine receptor antagonist. ST 1535 shows antiparkinsonian activity and antitremorigenic effects. ST 1535 has the potential for the research of Parkinson’s disease[1][2]. |
| Name | 2-butyl-9-methyl-8-(triazol-2-yl)purin-6-amine |
|---|---|
| Synonym | More Synonyms |
| Description | ST 1535 is a potent and orally active A2A adenosine receptor antagonist. ST 1535 shows antiparkinsonian activity and antitremorigenic effects. ST 1535 has the potential for the research of Parkinson’s disease[1][2]. |
|---|---|
| Related Catalog | |
| Target |
A2a adenosine receptor |
| In Vitro | ST 1535 (0-1000 nM) 抑制 CHO 细胞中 forskolin (HY-15371) 诱导的 cAMP 的形成，对 hA1, hA2A, hA2B, hA3 的 IC50 值分别为 510, 353, 950, >1000 nM[1]。 |
| In Vivo | ST 1535 (0, 5, 10 mg/kg; 口服) 拮抗 A2A 腺苷激动剂 CGS 21680 (HY-13201) (i.c.v.) 诱发的僵直症[1]。 ST 1535 (10、20、40 mg/kg；腹腔注射) 增加在大鼠中 l-DOPA (HY-N0304) 引起的对侧转动次数[2]。 Animal Model: 5-6 weeks CD1 male mice[1] Dosage: 0, 5, 10 mg/kg Administration: P.o. Result: Antagonized catalepsy induced by i.c.v. administration with the A2A adenosine agonist CGS 21680. Animal Model: Male Sprague Dawley rats[2] Dosage: 10, 20, 40 mg/kg Administration: I.p. Result: Significantly increased the number of contralateral turns induced by l-DOPA (3 mg/kg i.p.) at 20 and 40 mg/kg. |
| References |
| Molecular Formula | C12H16N8 |
|---|---|
| Molecular Weight | 272.30900 |
| Exact Mass | 272.15000 |
| PSA | 100.33000 |
| LogP | 1.45000 |
| st-1535 |